Neural autoantibody clusters aid diagnosis of cancer

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3862-3869

  Horta, Erika S ^a   Lennon, Vanda A ^a,b   Lachance, Daniel H ^a   Jenkins, Sarah M ^c   Smith, Carin Y ^c   McKeon, Andrew ^a   Klein, Christopher ^a   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; AUTOANTIBODY; CALCIUM CHANNEL N TYPE ANTIBODY; CALCIUM CHANNEL P TYPE ANTIBODY; CALCIUM CHANNEL Q TYPE ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; HU ANTIBODY; IMMUNOGLOBULIN G; NEURAL AUTOANTIBODY; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR SOX1; UNCLASSIFIED DRUG; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR; TUMOR MARKER;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL EVALUATION; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK ASSESSMENT; THYMOMA; TONSIL CANCER; BLOOD; CLUSTER ANALYSIS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; SKELETAL MUSCLE; TONSILLAR NEOPLASMS;

AUTOANTIBODIES; CALCIUM CHANNELS; CLUSTER ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUSCLE, SKELETAL; RECEPTORS, CHOLINERGIC; THYMOMA; TONSILLAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904396625     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0652     Document Type: Article

References (17)

1. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56: 715-9. (Pubitemid 39540753)
2. McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011;122:381-400.
3. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-7.
4. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580-7. (Pubitemid 36529431)
5. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50:301-11. (Pubitemid 32848732)
6. Lachance DH, Kryzer TJ, Pittock SJ, Chan KH, Lennon VA. Antineuronal nuclear antibody type 4 (ANNA-4), a novel paraneoplastic marker of SCLC. Neurology 2006;66:A340.
7. Sabater L TM, Saiz A, Verschuuren J, Güre A O, Graus F. SOX 1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008;70:924-8.
8. Cikes N, Momoi MY, Williams CL, Howard FM Jr, Hoagland HC, Whittingham S, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988;63:474-81.
9. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54. (Pubitemid 32157990)
10. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96-107. (Pubitemid 40962465)
11. Lennon VA. Calcium channel and related paraneoplastic disease autoantibodies. In:Peter JB, Schoenfeld Y, editors. Textbook of autoantibodies. Amsterdam, the Netherlands: Elsevier Science Publishers, B.V.; 1996. p. 139-47.
12. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343: 847-55.
13. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26: 1054-9.
14. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
15. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80: 412-6.
16. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997;48: S23-S7.
17. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-5. (Pubitemid 39487714)